M. van Glabbeke

Medicine · Health Sciences

71h-index45.8kcitations247works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(80), Lymphoma Diagnosis and Treatment(51), Gastrointestinal Tumor Research and Treatment(44), Vascular Tumors and Angiosarcomas(38), Gastric Cancer Management and Outcomes(21)

Publications247 total

Supplementary Figure 1 from Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
2023Open Access
Data from Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
2023Open Access
Supplementary Figure 2 from Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
2023Open Access
Supplementary Data from Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
2023Open Access
Supplementary Figure 2 from Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
2023Open Access
Data from Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
2023Open Access
Supplementary Data from Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
2023Open Access
Supplementary Figure 1 from Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
2023Open Access
Data from Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
2023Open Access
Data from Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
2023Open Access
European Organization for Research on Treatment of Cancer Trials Using Radiotherapy with Multiple Fractions per Day
Frontiers of radiation therapy and oncology·2015· 71 cited
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Annals of Oncology·2014· 52 citedOpen Access
Professor Maurice Staquet, MD, MS (1930 – 2013)
Statistics in Medicine·2013
Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931
European Journal of Cancer·2012· 40 cited
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Clinical Cancer Research·2012· 232 citedOpen Access
Achievements of the EORTC Soft Tissue and Bone Sarcoma Group
European Journal of Cancer Supplements·2012· 1 citedOpen Access
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
European Journal of Cancer·2011· 50 citedOpen Access
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials
Annals of Oncology·2011· 201 citedOpen Access
9400 ORAL Prognostic and Predictive Factors in Advanced Soft Tissue Sarcoma Patients Treated in an EORTC STBSG Global Network Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo (EORTC 62072, PALETTE)
European Journal of Cancer·2011
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma
British Journal of Cancer·2011· 34 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Jaap Verweij(25), Ian Judson(18), Jean‐Yves Blay(14), Pancras C.W. Hogendoorn(10), Raf Sciot(8), Allan T. van Oosterom(7), Ole S. Nielsen(7), Axel Le Cesne(7), Paolo G. Casali(6), A. van Oosterom(6), Axel Le Cesne(5), Peter Hohenberger(5), Peter Reichardt(4), Eugenio Donato Di Paola(4), Saša Dimitrijević(4), Maria Dêbiec‐Rychter(4), M. Schlemmer(4), Ivana Teodorović(4), A.T. van Oosterom(4), J. Wolter Oosterhuis(4)